Novyra Pharmachem Reports Q1FY27 Loss on Strong Pharma Segment Revenue Growth
Bansisons Tea Industries Ltd · Financial Result · 14 Aug 2026, 11:43 pm
Novyra Pharmachem Reports Q1FY27 Loss on Strong Pharma Segment Revenue Growth Novyra Pharmachem reported a net loss of ₹1.99 Lakhs for Q1FY27, a slight improvement from a ₹533.83 Lakh loss in Q4FY26 but worse than the ₹0.77 Lakh loss in Q1FY26. Revenue from operations surged to ₹172.61 Lakhs, up significantly from ₹3.00 Lakhs YoY and ₹10.44 Lakhs QoQ. The growth was driven by the Pharma segment, which generated ₹172.61 Lakhs in revenue and a profit of ₹1.29 Lakhs. The overall loss was due to large losses in the now-discontinued Tea Estate segment in previous periods.
Original exchange filing (PDF)
More announcements from Bansisons Tea Industries Ltd
- Unaudited Financial Results for the quarter ended September 30, 2026 · 02 Nov 2026
- Unaudited financial results for the quarter ended September 30, 2026 · 02 Nov 2026
- Novyra Pharmachem Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/11/2026 ,inter alia, to consider and approve Un-Audited Financial Results .... · 02 Nov 2026
- Intimation under Reg 30 · 24 Sept 2026
- Reg 30 · 22 Aug 2026
- Quarterly Results June 30, 2026 · 14 Aug 2026
- Bansisons Tea Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve Quarterly Results June 30, 2026 · 14 Aug 2026
- Change of Website · 04 Aug 2026
